Date:2/5/2009

d Future Number of FDC Drugs in Development -- Additive vs. Synergistic Effects -- Bioequivalence vs. Clinical Evaluation (Preferences and reasons why) -- Starting Development Prior vs. Post Patent Expiration -- Use of External Consultants -- Bioequivalence -- Timeframe from Conception to Final Formulation Launch -- Clinical Evaluation -- Timeframe from Conception to Final Formulation Launch -- Bioequivalence -- Timeframe from Initiating Formulation Development to Final Formulation Launch -- Clinical Evaluation -- Timeframe from Initiating Formulation Development to Final Formulation Launch -- Bioequivalence -- Multiple Metrics -- Clinical Evaluation -- Multiple Metrics -- Number of Drugs, FTEs and Timeframe to Reach First/Second Pilot PK Study -- Number of Drugs, FTEs and Timeframe to Reach Pivotal BE Study -- Number of FTEs in Analytical Development -- Timeframe from Initiating Development Work to CTM Manufacturing for Class 1/2/4 drugs

For more information on this study or the Best Practices, contact Ben Gregory at bgregory@best-in-class.com or (919) 767-9160. To access a full copy of the report or download a free excerpt, click the following link: http://www3.best-in-class.com/re938.htm .

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our
'/>"/>

SOURCE Best Practices, LLC Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. New Study Provides Benchmarks for Optimizing Marketing Staff Levels to Drive Growth
2. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
3. Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant
4. New Study Provides Benchmarks for Winning Brand Team Management
5. New Study Shares Insights for Competitive Intelligence Policies, Ethics and Data Collection
6. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
7. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
8. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
9. Clinical Research Study Focuses on Little Known Behavioral Changes Related to Parkinsons Disease
10. Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study
11. Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay